Mohammed M. Aboudeif: The Decision-Making Process for Anticoagulation in Stroke
Mohammed M. Aboudeif, Critical Care Registrar at King AbdulAziz University, shared on LinkedIn:
”Timing is often the most critical factor in neurocritical care, especially when balancing the risk of recurrent ischemia against the threat of hemorrhagic transformation.
Standardizing the transition from acute management to long-term prevention is essential for patient safety and clinical excellence.
This visual guide breaks down the decision-making process for Anticoagulation in Stroke, specifically focusing on the initiation of DOACs in patients with Atrial Fibrillation (AF).
Key Takeaways for the Clinical Team:
- The Acute Phase (0-48h): A universal ‘No’ for anticoagulation.
- The focus remains on stabilization, hydration, and DVT prophylaxis (IPC preferred).
Ischemic Stroke and AF
The 1-3-6-12 Rule remains a vital framework for starting DOACs based on stroke severity:
- Day 1: TIA
- Day 3: Mild (NIHSS <8)
- Day 6: Moderate (NIHSS 8-15)
- Day 12: Severe (NIHSS >15)
Hemorrhagic Stroke: A much more conservative approach.
Restarting anticoagulation is generally deferred for 2–4 weeks and reserved for those with high embolic risk (e.g., mechanical valves), requiring careful reassessment of re-bleeding risk.
Standardized protocols like these reduce clinical variability and improve outcomes in the ICU and beyond.”
Stay updated with Hemostasis Today.
-
Sep 5, 2026, 11:51Alejandro González Veliz: Why Secondary Prevention Matters After PCI
-
Sep 5, 2026, 11:39Julie Rayes: Sepsis Rewrites the Role of Mast Cells in Thrombosis
-
Sep 5, 2026, 11:30Shirley D’Sa: Chemoimmunotherapy in Cold Agglutinin Disease and WM-Associated CAS
-
Sep 5, 2026, 11:29Dilini Christina Ranasinghe: An Exception to the ‘Universal Donor’ – Bombay (Oh)
-
Sep 5, 2026, 11:10Amanda Stahl: Integrating Psychosocial Care Into Comprehensive Hemophilia Treatment
-
Sep 5, 2026, 10:23Danny Hsu: Honouring Rob Bird’s Career and Impact in Haematology
-
Sep 5, 2026, 10:12Wolfgang Miesbach: Can Emicizumab Be Used During Breastfeeding?
-
Sep 5, 2026, 09:52Lorena Arranz: Shaping the Future of Hematology with EHA 2027
-
Sep 5, 2026, 07:35Anticoagulation and Contemporary Secondary Prevention of Thrombosis in Polycythemia Vera